Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Praulent

Novartis building

CHMP backs Xolair for severe hives

Novartis set to expand indications for asthma drug

- PMLiVE

Amgen cholesterol antibody scores in another phase III trial

Evolocumab effective in patients who cannot take statins

Novartis building

New York plant set to close as Novartis continues cutbacks

More than 500 employees face the axe

- PMLiVE

NICE recommends Sanofi’s oral MS drug

Aubagio backed for NHS use in England and Wales

- PMLiVE

EU clears Gilead’s hepatitis C therapy Sovaldi

Region’s first all-oral treatment approved to treat the virus

Sanofi reception

Sanofi forms antibiotic research partnership

Will team up with Germany’s Fraunhofer-Gesellschaft to develop naturally-derived substances

Bayer symbol

Bayer and Regeneron to develop second wet AMD therapy

Will collaborate on drug to be used in combination with Eylea

- PMLiVE

Peacock steps down as Amgen CFO

Michael Kelly appointed acting financial head

Sanofi reception

Sanofi strikes $700m rare diseases deal

Company's Genzyme division will obtain significant rights to Alnylam’s pipeline of orphan drugs

- PMLiVE

Novartis cancer chief Hoppenot leaves for top job at Incyte

He ends 10-year spell at Swiss pharma giant

- PMLiVE

Genzyme shocked by FDA’s rejection of Lemtrada

US regulator refuses to approve MS drug on safety grounds

- PMLiVE

ABPI reprimands for four pharma firms

Allergan, Shire Pharmaceuticals, Gedeon Richter and Sanofi breach Code of Practice

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links